Bcr-Abl oncogene stimulates jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 2849-2856

  Yang, Kuei Ting ^a   Wang, Ming Chung ^b   Chen, Jing Yi ^a   Hsu, Ming Chuan ^c   Hung, Wen Chun ^a,d  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BCR ABL PROTEIN; BETA CATENIN; IMATINIB; JAP1 PROTEIN; MESSENGER RNA; STAT1 PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CELL LINE, TUMOR; CHROMONES; DOWN-REGULATION; ENZYME INHIBITORS; FLAVONOIDS; FUSION PROTEINS, BCR-ABL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORPHOLINES; ONCOGENE PROTEIN V-AKT; PEPTIDE HYDROLASES; PIPERAZINES; PROMOTER REGIONS, GENETIC; PYRIMIDINES; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 80051934411     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22633     Document Type: Article

References (32)

1. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. 2002. Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 277: 9-12.
2. Bertz J, Zang C, Liu H, Wächter M, Possinger K, Koeffler HP, Elstner E. 2009. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. Leuk Res 33: 686-692.
3. Carlesso N, Frank DA, Griffin JD. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183: 811-820.
4. Chang HC, Chang FR, Wang YC, Pan MR, Hung WC, Wu YC. 2007. A bioactive withanolide Tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression. Mol Cancer Ther 6: 1572-1578.
5. Chen JY, Wang MC, Hung WC. 2009. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leuk Res 33: 1520-1524.
6. Chen JY, Wang MC, Hung WC. 2011. Bcr-Abl induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J Cell Physiol 226: 407-413.
7. Claret FX, Hibi M, Dhut S, Toda T, Karin M. 1996. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383: 453-457.
8. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, Capeau J. 2001. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259.
9. Diehl JA, Cheng M, Roussel MF, Sherr CJ. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12: 3499-3511.
10. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. 2003. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res 9: 5652-5659.
11. Frank DA, Varticovski L. 1996. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10: 1724-1730.
12. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY, Nakajima Y. 2004. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 11: 277-284.
13. Hsu MC, Chang HC, Hung WC. 2006. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J Biol Chem 281: 4718-4725.
14. Hsu MC, Chang HC, Hung WC. 2007. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells. Endocr Relat Cancer 14: 655-667.
15. Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. 2008. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Clin Cancer Res 14: 4045-4052.
16. Jonulet T, van der Kulp H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE. 2000. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 96: 1933-1999.
17. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. 2003. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 63: 2977-2981.
18. Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339-345.
19. Liu LT, Chang HC, Chiang LC, Hung WC. 2003. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63: 3069-3072.
20. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW, Song J. 2006. Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem 281: 17457-17465.
21. Rangatia J, Bonnet D. 2006. Transient or long-term silencing of BCR-ABL alone induces cell and proliferation arrest, apoptosis and differentiation. Leukemia 20: 68-76.
22. Ren R. 2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous Leukemia. Nature Rev Cancer 5: 172-183.
23. Seeger M, Kraft R, Ferrell K, Decker SJ, Drebin JA, Greene MI, Weinberg RA. 1998. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 12: 469-478.
24. Sengupta A, Banerjee D, Chandra S, Banerjee S. 2006. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. J Gene Med 8: 1251-1261.
25. Skurk C, Maatz H, Rocnik E, Bialik A, Force T, Walsh K. 2005. Glycogen-synthase kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res 96: 308-318.
26. Tian Q, Feetham MC, Tao WA, He XC, Li L, Aebersold R, Hood L. 2004. Proteomic analysis identifies that 14-3-3zeta interacts with beta-catenin and facilitates its activation by Akt. Proc Natl Acad Sci USA 101: 15370-15375.
27. Tomoda K, Kubota Y, Kato J. 1999. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398: 160-165.
28. Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N. 2005. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell cycle progression. Blood 105: 775-783.
29. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N, Cao X. 2002. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep 3: 171-176.
30. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J. 1996. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816.
31. Wei N, Tsuge T, Serino G, Dohmae N, Takio K, Matsui M, Deng XW. 1998. The COP9 complex is conserved between plants and mammals and is related to the 26S proteasome regulatory complex. Curr Biol 8: 919-922.
32. Zang C, Liu H, Waechter M, Eucker J, Bertz J, Possinger K, Koeffler HP, Elstner E. 2006. Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. Cell Cycle 5: 2237-2243.